Investors were disappointed with Abbott Laboratories' ( NYSE:ABT ) earnings, despite the strong profit numbers.

Abbott Laboratories (NYSE:ABT) is one of the top low volatility healthcare stocks to buy now. Analyst Mike Kratky from ...

Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the medical devices & supplies - diversified stocks, ...

For traders who focus on events, examining the historical reactions of the stock to earnings announcements can offer useful insights.

With this in mind, three Motley Fool contributors have identified dividend stocks that they think retirees should absolutely love. Here's why they picked Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ...

The company reported strong earnings in the second quarter of 2025. It posted revenue of $11.1 billion, which showed a 7.37% ...

An Abbott official said today that the company launched its latest-generation MitraClip and TriClip G5 systems.

Abbott Laboratories (NYSE: ABT) is reporting before the market opens and we’ll be updating this article with live analysis. So far, the stock is up 16.1% in 2025.

Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below consensus. Read more here.

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin guidance was cut. Learn more on ABT stock here.

Abbott Laboratories (NYSE:ABT – Get Free Report) was upgraded by research analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a research report issued on ...